Sun Pharma FY26 Net Profit Rises 5% to Rs 114,794 Million
Sun Pharmaceutical Industries reported its audited financial results for the quarter and year ended March 31, 2026, with FY26 revenue rising 11.9% to Rs. 582,201 million and net profit increasing 5.0% to Rs. 114,794 million. The Board recommended a final dividend of Rs. 5.00 per share, bringing the total dividend for the year to Rs. 16.00 per share.
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries reported its audited financial results for the quarter and year ended March 31, 2026. The company recorded consolidated revenue of Rs. 582,201 million for the full year, an increase of 11.9% compared to Rs. 520,413 million in the previous year. For the fourth quarter, revenue stood at Rs. 146,118 million, reflecting a year-on-year increase from Rs. 129,588 million.
Financial Performance at a Glance
The key financial metrics for the year and quarter are summarised below:
| Metric: | FY26 Current | FY25 Previous | Q4 Current | Q4 Previous |
|---|---|---|---|---|
| Revenue: | Rs. 582,201 million | Rs. 520,413 million | Rs. 146,118 million | Rs. 129,588 million |
| Net Profit: | Rs. 114,794 million | Rs. 109,290 million | Rs. 27,140 million | Rs. 21,499 million |
| EBITDA: | Rs. 177,314 million | Rs. 152,717 million | Rs. 39,542 million | Rs. 37,161 million |
| EBITDA Margin: | 30.3% | 29.0% | 27.1% | 28.7% |
Profitability and Operational Highlights
The company's consolidated net profit for FY26 rose to Rs. 114,794 million, a 5.0% increase from the prior year. Q4 net profit grew 26.2% year-on-year to Rs. 27,140 million. EBITDA for the full year increased by 16.1% to Rs. 177,314 million, with the margin expanding to 30.3%. However, the Q4 EBITDA margin narrowed to 27.1% from 28.7% in the year-ago period.
Dividend Declaration
The Board of Directors has recommended a final dividend of Rs. 5.00 per equity share of Rs. 1 each for the financial year 2025-26. This is in addition to the interim dividend of Rs. 11.00 per share declared earlier, bringing the total dividend for FY26 to Rs. 16.00 per share. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.47% | -1.00% | +10.77% | +3.65% | +6.51% | +167.18% |
How might potential US tariffs on pharmaceutical imports impact Sun Pharma's revenue growth trajectory in FY27, given its significant US market exposure?
What strategic acquisitions or pipeline investments is Sun Pharma likely to pursue to sustain its 30%+ EBITDA margin beyond FY26?
Will the Q4 EBITDA margin contraction signal a structural cost pressure trend, or is it likely to recover as specialty drug launches gain traction in coming quarters?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
